Preamble to the 2015 SITC immunotherapy biomarkers taskforce

Lisa H. Butterfield; Mary L. Disis; Bernard A. Fox; Samir N. Khleif; Francesco M. Marincola

doi:10.1186/s40425-015-0052-6

Preamble to the 2015 SITC immunotherapy biomarkers taskforce

Lisa H. Butterfield, Mary L. Disis, Bernard A. Fox, Samir N. Khleif, Francesco M. Marincola

Research output: Contribution to journal › Comment/debate › peer-review

3 Scopus citations

Abstract

The Society for Immunotherapy of Cancer (SITC) has regularly hosted workshops and working groups focused on immunologic monitoring and immune biomarkers. Due to advances in cancer immunotherapy, including positive results from clinical trials testing new agents and combinations, emerging new technologies for measuring aspects of immunity, and novel candidate biomarkers from early phase trials, the SITC Immune Biomarkers Taskforce has reconvened to review the state of the art, identify current hurdles to further success and to make recommendations to the field. Topics being addressed by individual working groups include: (1) validation of candidate biomarkers, (2) identification of the most promising technologies, (3) testing of high throughput immune signatures and (4) investigation of the pre-treatment tumor microenvironment. Resultant recommendations will be published in JITC.

Original language	English (US)
Article number	8
Journal	Journal for ImmunoTherapy of Cancer
Volume	3
Issue number	1
DOIs	https://doi.org/10.1186/s40425-015-0052-6
State	Published - Mar 24 2015

Keywords

Biomarkers
Clinical trial
Immune monitoring
Immunotherapy
Taskforce

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Molecular Medicine
Oncology
Pharmacology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/s40425-015-0052-6

Cite this

@article{4ee77314259d463294629ce3218e5825,

title = "Preamble to the 2015 SITC immunotherapy biomarkers taskforce",

abstract = "The Society for Immunotherapy of Cancer (SITC) has regularly hosted workshops and working groups focused on immunologic monitoring and immune biomarkers. Due to advances in cancer immunotherapy, including positive results from clinical trials testing new agents and combinations, emerging new technologies for measuring aspects of immunity, and novel candidate biomarkers from early phase trials, the SITC Immune Biomarkers Taskforce has reconvened to review the state of the art, identify current hurdles to further success and to make recommendations to the field. Topics being addressed by individual working groups include: (1) validation of candidate biomarkers, (2) identification of the most promising technologies, (3) testing of high throughput immune signatures and (4) investigation of the pre-treatment tumor microenvironment. Resultant recommendations will be published in JITC.",

keywords = "Biomarkers, Clinical trial, Immune monitoring, Immunotherapy, Taskforce",

author = "Butterfield, {Lisa H.} and Disis, {Mary L.} and Fox, {Bernard A.} and Khleif, {Samir N.} and Marincola, {Francesco M.}",

note = "Publisher Copyright: {\textcopyright} 2015 Butterfield et al.",

year = "2015",

month = mar,

day = "24",

doi = "10.1186/s40425-015-0052-6",

language = "English (US)",

volume = "3",

journal = "Journal for ImmunoTherapy of Cancer",

issn = "2051-1426",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - Preamble to the 2015 SITC immunotherapy biomarkers taskforce

AU - Butterfield, Lisa H.

AU - Disis, Mary L.

AU - Fox, Bernard A.

AU - Khleif, Samir N.

AU - Marincola, Francesco M.

PY - 2015/3/24

Y1 - 2015/3/24

N2 - The Society for Immunotherapy of Cancer (SITC) has regularly hosted workshops and working groups focused on immunologic monitoring and immune biomarkers. Due to advances in cancer immunotherapy, including positive results from clinical trials testing new agents and combinations, emerging new technologies for measuring aspects of immunity, and novel candidate biomarkers from early phase trials, the SITC Immune Biomarkers Taskforce has reconvened to review the state of the art, identify current hurdles to further success and to make recommendations to the field. Topics being addressed by individual working groups include: (1) validation of candidate biomarkers, (2) identification of the most promising technologies, (3) testing of high throughput immune signatures and (4) investigation of the pre-treatment tumor microenvironment. Resultant recommendations will be published in JITC.

AB - The Society for Immunotherapy of Cancer (SITC) has regularly hosted workshops and working groups focused on immunologic monitoring and immune biomarkers. Due to advances in cancer immunotherapy, including positive results from clinical trials testing new agents and combinations, emerging new technologies for measuring aspects of immunity, and novel candidate biomarkers from early phase trials, the SITC Immune Biomarkers Taskforce has reconvened to review the state of the art, identify current hurdles to further success and to make recommendations to the field. Topics being addressed by individual working groups include: (1) validation of candidate biomarkers, (2) identification of the most promising technologies, (3) testing of high throughput immune signatures and (4) investigation of the pre-treatment tumor microenvironment. Resultant recommendations will be published in JITC.

KW - Biomarkers

KW - Clinical trial

KW - Immune monitoring

KW - Immunotherapy

KW - Taskforce

UR - http://www.scopus.com/inward/record.url?scp=84977100953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977100953&partnerID=8YFLogxK

U2 - 10.1186/s40425-015-0052-6

DO - 10.1186/s40425-015-0052-6

M3 - Comment/debate

AN - SCOPUS:84977100953

SN - 2051-1426

VL - 3

JO - Journal for ImmunoTherapy of Cancer

JF - Journal for ImmunoTherapy of Cancer

IS - 1

M1 - 8

ER -

Preamble to the 2015 SITC immunotherapy biomarkers taskforce

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this